{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:17:27Z","timestamp":1783495047092,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was supported by internal funding of the University Heart Center\/Medical Center \u2013 University of Freiburg."},{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>GLP-1 receptor agonists (GLP-1 RA) reduce major adverse cardiovascular events in patients with diabetes mellitus and atherosclerotic cardiovascular disease (ASCVD) or increased cardiovascular risk. Recently, the GLP-1 RA semaglutide was reported to reduce cardiovascular events in ASCVD patients with overweight or obesity even in the absence of diabetes mellitus. Accordingly, this was included in the current European Society of Cardiology guidelines for secondary prevention. We aimed to assess the number of inpatients with ASCVD who could qualify for therapy with GLP-1\u00a0RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using nationwide data from the Research Data Centre of the Federal Statistical Office of Germany, a random 10% sample of all adult inpatients in 2022 was analyzed. The proportions of ASCVD, obesity, and diabetes mellitus were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 10% sample included 1,446,420 patients with a mean age of 63.16 years, 52.50% were female. ASCVD was present in 229,619 inpatients (15.87%), including those with coronary artery disease, history of myocardial infarction, peripheral vascular disease or stroke. Among ASCVD patients, 79,516 individuals (34.63% of ASCVD patients) also suffered from type 2 diabetes mellitus and 15,624 individuals were diagnosed with obesity. Approximately half of those (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20097,256) had ASCVD and obesity without diabetes mellitus (3.16% of ASCVD patients). Overall, 37.79% of ASCVD patients also suffered from type 2 diabetes mellitus or obesity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this data sampling of German inpatients, more than one-third of ASCVD patients may qualify for GLP-1 RA therapy due to concomitant diabetes mellitus or obesity. That corresponds to about 6% of inpatients in Germany.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-025-02735-z","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T09:06:31Z","timestamp":1755767191000},"page":"1343-1350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 receptor agonists in atherosclerotic cardiovascular disease and diabetes mellitus or obesity: investigation of the potential role in a German inpatient dataset"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-2102","authenticated-orcid":false,"given":"Vera","family":"Oettinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2767-8009","authenticated-orcid":false,"given":"Constantin","family":"von zur M\u00fchlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-6945","authenticated-orcid":false,"given":"Klaus","family":"Kaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1525-4348","authenticated-orcid":false,"given":"Dennis","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-3629","authenticated-orcid":false,"given":"Jonathan","family":"Rilinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0200-7495","authenticated-orcid":false,"given":"Alexander","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8638-5228","authenticated-orcid":false,"given":"Markus","family":"J\u00e4ckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7542-1956","authenticated-orcid":false,"given":"Dirk","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-1643","authenticated-orcid":false,"given":"Ingo","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalibor","family":"Bockelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"2","key":"2735_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 41(2):255\u2013323","journal-title":"Eur Heart J"},{"issue":"2_suppl","key":"2735_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"E Dal Canto","year":"2019","unstructured":"Dal Canto E, Ceriello A, Ryd\u00e9n L et al (2019) Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 26(2_suppl):25\u201332","journal-title":"Eur J Prev Cardiol"},{"issue":"21","key":"2735_CR3","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE et al (2021) Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 143(21):e984\u2013e1010","journal-title":"Circulation"},{"issue":"17","key":"2735_CR4","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1093\/eurjpc\/zwac187","volume":"29","author":"F Lopez-Jimenez","year":"2022","unstructured":"Lopez-Jimenez F, Almahmeed W, Bays H et al (2022) Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol 29(17):2218\u20132237","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"2735_CR5","doi-asserted-by":"publisher","first-page":"100655","DOI":"10.1016\/j.cpcardiol.2020.100655","volume":"46","author":"N Katta","year":"2021","unstructured":"Katta N, Loethen T, Lavie CJ, Alpert MA (2021) Obesity and coronary heart disease: epidemiology, pathology, and coronary artery imaging. Curr Probl Cardiol 46(3):100655","journal-title":"Curr Probl Cardiol"},{"key":"2735_CR6","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S et al (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119","journal-title":"Diabetes Res Clin Pract"},{"issue":"10431","key":"2735_CR7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","author":"NH Phelps","year":"2024","unstructured":"Phelps NH, Singleton RK, Zhou B et al (2024) Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403(10431):1027\u20131050","journal-title":"Lancet"},{"issue":"9921","key":"2735_CR8","first-page":"970","volume":"383","author":"Y Lu","year":"2013","unstructured":"Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G (2014) Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1\u00b78 million participants. Lancet 383(9921):970\u2013983","journal-title":"Lancet (London, England)"},{"issue":"12","key":"2735_CR9","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jacc.2017.07.763","volume":"70","author":"R Caleyachetty","year":"2017","unstructured":"Caleyachetty R, Thomas GN, Toulis KA et al (2017) Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J Am Coll Cardiol 70(12):1429\u20131437","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2735_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9(10):653\u2013662","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"19","key":"2735_CR11","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844","journal-title":"N Engl J Med"},{"issue":"4","key":"2735_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u2013322","journal-title":"N Engl J Med"},{"issue":"10193","key":"2735_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130","journal-title":"Lancet"},{"issue":"11","key":"2735_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JP Wilding","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989\u20131002","journal-title":"N Engl J Med"},{"issue":"10278","key":"2735_CR15","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK et al (2021) Semaglutide\u00a02\u00b74 mg\u00a0once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278):971\u2013984","journal-title":"Lancet"},{"issue":"14","key":"2735_CR16","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK et al (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 325(14):1403\u20131413","journal-title":"JAMA"},{"issue":"14","key":"2735_CR17","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M et al (2021) Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325(14):1414\u20131425","journal-title":"JAMA"},{"issue":"10","key":"2735_CR18","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M et al (2022) Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28(10):2083\u20132091","journal-title":"Nat Med"},{"issue":"11","key":"2735_CR19","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S et al (2013) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond) 37(11):1443\u20131451","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"2735_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373(1):11\u201322","journal-title":"N Engl J Med"},{"issue":"7","key":"2735_CR21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B et al (2015) Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314(7):687\u2013699","journal-title":"JAMA"},{"issue":"8","key":"2735_CR22","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman A, Foster G, Zammit G et al (2016) Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial.\u00a0Int J Obes (Lond)\u00a040(8):1310\u20131319","journal-title":"Int J Obes"},{"issue":"3","key":"2735_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387(3):205\u2013216","journal-title":"N Engl J Med"},{"issue":"10402","key":"2735_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM et al (2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 402(10402):613\u2013626","journal-title":"Lancet"},{"issue":"11","key":"2735_CR25","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S et al (2023) Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 29(11):2909\u20132918","journal-title":"Nat Med"},{"issue":"1","key":"2735_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB et al (2024) Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 331(1):38\u201348","journal-title":"JAMA"},{"issue":"24","key":"2735_CR27","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389(24):2221\u20132232","journal-title":"N Engl J Med"},{"issue":"36","key":"2735_CR28","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC et al (2024) 2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 45(36):3415\u20133537","journal-title":"Eur Heart J"},{"issue":"39","key":"2735_CR29","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J 44(39):4043\u20134140","journal-title":"Eur Heart J"},{"key":"2735_CR30","doi-asserted-by":"publisher","first-page":"3723657","DOI":"10.1155\/2023\/3723657","volume":"2023","author":"V Oettinger","year":"2023","unstructured":"Oettinger V, Hehn P, Bode C et al (2023) Center Volumes Correlate with Likelihood of Stent Implantation in German Coronary Angiography. J Interv Cardiol 2023:3723657","journal-title":"J Interv Cardiol"},{"issue":"42","key":"2735_CR31","first-page":"704","volume":"113","author":"C Dornquast","year":"2016","unstructured":"Dornquast C, Kroll LE, Neuhauser HK, Willich SN, Reinhold T, Busch MA (2016) Regional differences in the prevalence of cardiovascular disease: results from the German health update (GEDA) from 2009\u20132012. Dtsch Arztebl Int 113(42):704","journal-title":"Dtsch Arztebl Int"},{"issue":"7","key":"2735_CR32","first-page":"207","volume":"121","author":"MJ Stein","year":"2024","unstructured":"Stein MJ, Fischer B, Bohmann P et al (2024) Differences in anthropometric measures based on sex, age, and health status: findings from the german national cohort (NAKO). Dtsch Arztebl Int 121(7):207\u2013213","journal-title":"Dtsch Arztebl Int"},{"issue":"11","key":"2735_CR33","first-page":"177","volume":"113","author":"T Tamayo","year":"2016","unstructured":"Tamayo T, Brinks R, Hoyer A, Ku\u00df O, Rathmann W (2016) The prevalence and incidence of diabetes in Germany: an analysis of statutory health insurance data on 65 million individuals from the years 2009 and 2010. Dtsch Arztebl Int 113(11):177","journal-title":"Dtsch Arztebl Int"},{"issue":"24","key":"2735_CR34","first-page":"407","volume":"118","author":"M Auzanneau","year":"2021","unstructured":"Auzanneau M, Fritsche A, Icks A et al (2021) Diabetes in the hospital: a nationwide analysis of all hospitalized cases in Germany with and without diabetes, 2015\u20132017. Dtsch Arztebl Int 118(24):407","journal-title":"Dtsch Arztebl Int"},{"issue":"10","key":"2735_CR35","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/dme.13902","volume":"36","author":"T T\u00f6nnies","year":"2019","unstructured":"T\u00f6nnies T, R\u00f6ckl S, Hoyer A et al (2019) Projected number of people with diagnosed type 2 diabetes in Germany in 2040. Diabet Med 36(10):1217\u20131225","journal-title":"Diabet Med"},{"issue":"1","key":"2735_CR36","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00392-023-02326-w","volume":"113","author":"V Oettinger","year":"2024","unstructured":"Oettinger V, Hilgendorf I, Wolf D et al (2024) Comparing balloon-expandable and self-expanding transfemoral transcatheter aortic valve replacement based on subgroups in Germany 2019\/2020. Clin Res Cardiol 113(1):168\u2013176","journal-title":"Clin Res Cardiol"},{"issue":"9","key":"2735_CR37","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s00392-020-01612-1","volume":"109","author":"JT Neumann","year":"2020","unstructured":"Neumann JT, Gossling A, Sorensen NA, Blankenberg S, Magnussen C, Westermann D (2020) Temporal trends in incidence and outcome of acute coronary syndrome. Clin Res Cardiol 109(9):1186\u20131192","journal-title":"Clin Res Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02735-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:05:05Z","timestamp":1783494305000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02735-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2735"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02735-z","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The investigators in this study did not have direct access to individual patient data for this analysis. Access was granted by Destatis only for summarized results. Ethics committee approval and informed consent were therefore not required according to German law. Destatis anonymised all pooled results and any information that could potentially identify an individual patient or an individual center has been censored by Destatis to ensure privacy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}